Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.

Justyna SiwyThomas KleinMarcel RoslerMaximilian von Eynatten

Published in: Proteomics. Clinical applications (2019)

CKD273 is a promising tool for identifying patients at high risk for CKD progression and may unmask a potential of linagliptin to slow progressive kidney function loss in high CKD-risk patients. UPP characterization reveals a significant impact of linagliptin on urinary peptides.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
prognostic factors
randomized controlled trial
mass spectrometry
open label
phase ii